Evaluation of Safety and Efficacy of Mersina, An Ayurvedic formulation: A double blind, placebo controlled study in type 2 diabetic patients with Secondary failure to Oral drugs
Phase 2
Completed
- Registration Number
- CTRI/2009/091/000560
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 26
Inclusion Criteria
Secondary failure to Oral Hypoglycemic Agents was diagnosed if the patient had HbA1c levels > 8.5% even after supplementation of maximal dose of a combination of a sulphonylurea (15 mg glybenclamide or 160 mg gliclazide or 15 mg glipizide) and metformin 1500 mg/day.
Exclusion Criteria
Patients with ketosis, diabetes related complications, hepatic or renal disease, pancreatitis, cardiac problems, uncontrolled hypertension, malnutrition and severe immune deficiency.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antidiabetic activityTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method Improvement in metabolic, insulin level, HbA1c level, kidney and lipid profileTimepoint: 3 months